The evaluation of new antituberculosis drugs in children

Progress in Respiratory Research

Volumn 40, Issue , 2011, Pages 235-242

  McNeeley, David F ^a   Raoof, Araz ^b   Lin, Jenny ^c   Marais, Ben J ^d  

^a Medical Service Corporation International   (United States)

^b TIBOTEC BVBA   (Belgium)

^c Tibotec Inc   (United States)

^d STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052922142     PISSN: 14222140     EISSN: 16623932     Source Type: Book Series    
DOI: 10.1159/000324637     Document Type: Review

References (38)

1. Nelson LJ, Wells CD: Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis 2004;8:636-647. (Pubitemid 38625076)
2. World Health Organization: Global Tuberculosis Control: Epidemiology, Strategy, Financing. Geneva, World Health Organization, 2009.
3. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B: Paediatric tuberculosis. Lancet Infect Dis 2008;8:499-510.
4. Marais BJ, Hesseling AC, Gie RP, Schaaf HS, Beyers N: The burden of childhood tuberculosis and the accuracy of routine surveillance data in a high-burden setting. Int J Tuberc Lung Dis 2006;10:259-263.
5. Marais BJ, Schaaf HS: Childhood tuberculosis: An emerging and previously neglected problem. Infect Dis Clin North Am 2010;24:727-749.
6. Chintu C, Mudenda V, Lucas S, Nunn A, Lishimpi K, Maswahu D, Kasolo F, Mwaba P, Bhat G, Terunuma H, Zumla A: Lung diseases at necropsy in African children dying from respiratory illnesses: A descriptive necropsy study. Lancet 2002;360:985-990. (Pubitemid 35284110)
7. McNally LM, Jeena PM, Gajee K, Thula SA, Sturm AW, Cassol S, Tomkins AM, Coovadia HM, Goldblatt D: Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: A prospective descriptive study. Lancet 2007;369:1440-1451. (Pubitemid 46635781)
8. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Enarson DA, Beyers N: The spectrum of childhood tuberculosis in a highly endemic area. Int J Tuberc Lung Dis 2006;10:732-738. (Pubitemid 44031385)
9. Lawn SD, Bekker LG, Middelkoop K, Myer L, Wood R: Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: The need for age-specific interventions. Clin Infect Dis 2006;42:1040-1047.
10. Marais BJ, Gupta A, Starke JR, El-Sony A: Tuberculosis in women and children. Lancet 2010;375:2057-2059.
11. Marais BJ, Rabie H, Cotton MF: TB and HIV in children -advances in prevention and management. Paediatr Respir Rev 2011;12:39-45.
12. Marais BJ, Raviglione M, Donald PR, Harries AD, Kritski AL, Graham SM, El-Sadr WM, Harrington M, Churchyard G, Mwaba P, Sanne I, Kaufmann SH, Whitty CJ, Atun R, Zumla A: Scale-up of services and research priorities for diagnosis, management and control of tuberculosis Call to action. Lancet 2010;375:2179-2191.
13. World Health Organization: Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. WHO/HTM/ TB/2006.371. Geneva, WHO, 2006.
14. Schaaf HS, Marais BJ, Hesseling AC, Gie RP, Beyers N, Donald PR: Childhood drug-resistant tuberculosis in the Western Cape Province of South Africa. Acta Paediatr 2006;95:523-528. (Pubitemid 43791572)
15. Gandhi N, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J: Multidrug-resistant and extensively drugresistant tuberculosis: A threat to global control of tuberculosis. Lancet 2010;375:1830-1843.
16. Gagneux G, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJM: The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006;312:1944-1946. (Pubitemid 43993719)
17. Marais BJ, Victor TC, Hesseling AC, Barnard M, Jordaan A, Brittle A, Reuter H, Beyers N, van Helden PD, Warren RM, Schaaf HS: Beijing and Haarlem genotypes are over-represented among children with drug resistant tuberculosis in the Western Cape Province of South Africa. J Clin Microbiol 2006;44:3539-3543. (Pubitemid 46768796)
18. Schaaf HS, Marais BJ, Hesseling AC, Brittle W, Donald PR: Surveillance of antituberculosis drug resistance among children from the Western Cape Province of South Africa -an upward trend. Am J Public Health 2009;99:1486-1490.
19. Gie RP, Matiru RH: Supplying quality-assured child-friendly anti-tuberculosis drugs to children. Int J Tuberc Lung Dis 2009;13:277-278.
20. McIlleron H, Willemse M, Werely CJ, Hussey GD, Schaaf HS, Smith PJ, Donald PR: Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: Implications for international pediatric dosing guidelines. Clin Infect Dis 2009;48:1547-1553.
21. Schaaf HS, Willemse M, Cilliers K, Labadarios D, Maritz JS, Hussey GD, McIlleron H, Smith P, Donald PR: Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med 2009;7:19.
22. Graham SM, Bell DJ, Nyirongo S, Hartkorn R, Ward SA, Molyneux EM: Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status and human immunodeficiency virus infection. Antimicrob Agents Chemother 2006;50:407-413. (Pubitemid 43190946)
23. Marais BJ, Schaaf HS, Donald PR: Pediatric tuberculosis: Issues related to current and future treatment options. Future Microbiol 2009;4:661-675.
24. http://ohsr.od.nih.gov/guidelines/nuremburg.html.
25. http://www.donoharm.org.uk/gendecl.htm.
26. http://ohsr.od.nih.gov/guidelines/belmont.html.
27. http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ FoodandDrugAdministrationAmendmentsActof2007/FullTextofFDAAALaw/default.htm.
28. http://ec.europa.eu/health/files/eudralex/vol-1/reg-2006-1901/ reg-2006-1901-en.pdf.
29. Reich M, Stefano V, Compagni A: Orphan drug legislation: Lessons for neglected tropical diseases. Int J Health Planning Manag, Wiley Interscience (April 24, 2008). http://www.wcfia.harvard. edu/sites/default/files/Reich- Orphan.pdf.
30. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500002926.pdf.
31. US FDA, Center for Drug Evaluation and Research: Guidance for industry, nonclinical safety evaluation of pediatric drug products. Rockville, US Department of Health and Human Services, February 2006.
32. European Medicines Evaluation Agency (EMEA), Committee for Human Medicinal Products (CHMP): Guideline on the need for nonclinical testing in juvenile animals on human pharmaceuticals for pediatric indications. January 2008.
33. USFDA: Guidance for industry: General considerations for pediatric pharmacokinetic studies for drugs and biological products. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, 1998.
34. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Guidance on non-clinical safety studies for the conduct of human clinical trials marketing authorization for pharmaceuticals M3 (R2). 2008.
35. Marais BJ, van Helden PD, Donald PR: Adequacy of 6 month follow-up in chemotherapy therapy trials. Int J Tuberc Lung Dis 2010;14:927-930.
36. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2010/01/WC500070049.pdf.
37. Donald PR: The assessment of new antituberculosis drugs in children. Int J Tuberc Lung Dis 2007;11:1162-1165. (Pubitemid 350146295)
38. Burman WJ, Cotton MF, Gibb DA, Walker AS, Vernon AA, Donald PR: Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens. PLoS Med 2008;5:e176.